These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 5002305)

  • 1. [Activity of rifampicin on experimental tuberculosis in mice. The development of resistance to rifampicin. Therapeutic effects of combinations of different drugs with rifampicin].
    Grumbach F
    Antibiot Chemother; 1970; 16():392-405. PubMed ID: 5002305
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary and acquired drug resistance in Mycobacterium tuberculosis strains in western region of Libyan Arab Jamahiriya.
    Elghoul MT; Joshi RM; Rizghalla T
    Trop Geogr Med; 1989 Oct; 41(4):304-8. PubMed ID: 2517554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Activity of the second-line preparations, ethambutol and rifampin, in experimental tuberculosis caused by Mycobacterium tuberculosis highly resistant to basic tuberculostatics].
    Golyshevskaia VI; El'shanskaia MP
    Probl Tuberk; 1973; 51(12):60-4. PubMed ID: 4205666
    [No Abstract]   [Full Text] [Related]  

  • 4. Rifampicin: a first line tuberculostatic drug. A critical review and appraisal.
    Saerens EJ
    Acta Tuberc Pneumol Belg; 1972; 63(6):516-28. PubMed ID: 4206441
    [No Abstract]   [Full Text] [Related]  

  • 5. The suitability of new drugs for intermittent chemotherapy of tuberculosis. An experimental study.
    Dickinson JM
    Scand J Respir Dis Suppl; 1969; 69():91-8. PubMed ID: 4190279
    [No Abstract]   [Full Text] [Related]  

  • 6. [Significance of isoniazid for the therapy of experimental infection with total INH- and SM- resistant human tuberculosis bacteria in the mice].
    Matsumiya T; Freerksen E; Rosenfeld M
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):14-29. PubMed ID: 4320557
    [No Abstract]   [Full Text] [Related]  

  • 7. An experimental attempt of intensified chemotherapy with rifampicin combined with other drugs.
    Hokama S
    Jpn J Tuberc Chest Dis; 1971 Jul; 17(1):57-61. PubMed ID: 5317096
    [No Abstract]   [Full Text] [Related]  

  • 8. [Survival of tuberculous bacilli in combined treatments including rifampicin].
    Kreis B; Pretet S
    Rev Tuberc Pneumol (Paris); 1970; 34(3):429-33. PubMed ID: 4994940
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experimental in-vitro and in-vivo studies of the antibacterial effect of rifampicin and ethambutol].
    Kozulicyna TI; Korotajev GA
    G Ital Chemioter; 1972; 19(2):7-10. PubMed ID: 4199030
    [No Abstract]   [Full Text] [Related]  

  • 10. Rifampicin activity "in vitro" and in established tuberculosis in mice.
    Verbist L
    Acta Tuberc Pneumol Belg; 1969; 60(3):397-412. PubMed ID: 4984420
    [No Abstract]   [Full Text] [Related]  

  • 11. [Rifampicine in tuberculosis. Peculiarity of its experimental activity and new therapeutic prospects].
    Le Lirzin M; Grumbach F
    Pathol Biol (Paris); 1972 Oct; 20(19):785-92. PubMed ID: 4628424
    [No Abstract]   [Full Text] [Related]  

  • 12. Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol.
    Dickinson JM; Mitchison DA
    Tubercle; 1976 Dec; 57(4):251-8. PubMed ID: 827836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifampin--a major new chemotherapeutic agent for the treatment of tuberculosis.
    Daniel TM
    N Engl J Med; 1969 Mar; 280(11):615-6. PubMed ID: 4974534
    [No Abstract]   [Full Text] [Related]  

  • 14. [Determination of resistance of Mycobacterium tuberculosis against isonicotinic acid hydrazide, streptomycin, para-aminosalicylic acid, ethionamide, ethambutol and rifampicin using the 32 P incorporation test].
    Reutgen H
    Acta Biol Med Ger; 1973; 30(3):309-16. PubMed ID: 4202698
    [No Abstract]   [Full Text] [Related]  

  • 15. Experimental and clinical studies on the antituberculous activity of rifampicin alone or combined with other drugs.
    Nitti V
    Antibiot Chemother; 1970; 16():444-70. PubMed ID: 5002308
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of in-vitro and in-vivo experiments with Mycobacterium tuberculosis in helping to plan chemotherapy regimens.
    Dickinson JM; Mitchison DA
    Tidsskr Nor Laegeforen; 1975 Jun; 95(17-18):1087-9. PubMed ID: 806991
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sensitivity to rifampicin and ethambutol of mycobacteria resistant to isoniazid or streptomycin].
    Golychevskaja VI
    G Ital Chemioter; 1972; 19(2):20-2. PubMed ID: 4199029
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001--2002).
    Negi SS; Gupta S; Lal S
    J Commun Dis; 2003 Jun; 35(2):74-81. PubMed ID: 15562952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of rifampicin and other antituberculous agents in chronic murine tuberculosis.
    Kradolfer F; Schnell R
    Chemotherapy; 1971; 16(3):173-82. PubMed ID: 5561406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.